Risk Profile Improvements
- Material Weakness (improved) — Material weakness persists but scope reduced from 4 third-party providers to 1, showing meaningful remediation progress.
- Goodwill Impairment (improved) — Prior year recorded $7.5M goodwill impairment; current year reports no goodwill impairment, indicating improved valuation.
OptimizeRx returns to profitability with $5.1M net income, doubles sales team to 50+
Filed March 12, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 20, 2025 · ~1 min read
Key Changes
-
high
Company returned to profitability with $5.1M net income in 2025 vs. $20.1M loss in 2024, driven by 19% revenue growth to $109.4M, improved 67% gross margin, and 15% lower operating expenses.
MD&A: Financial Results verify on EDGAR → -
high
Sales, marketing, and account management headcount doubled from 25+ to 50+ individuals, signaling aggressive investment in commercial capabilities to support growth.
Business: Sales Organization verify on EDGAR → -
high
Material weakness in internal controls improved: 3 of 4 third-party service provider issues resolved, but one remains unresolved due to inadequate data reporting controls.
Controls: Remediation Progress verify on EDGAR →
2 more material changes plus the full narrative summary — create a free account to see the rest. Takes 30 seconds.
Partner
Trade OPRX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 8, 2026 7:42 PM